Combination of MEK Inhibitor Binimetinib and CDK4/6
Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer »